The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Open accessAbstract
Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 down-regulates BRCA1 expression . Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by over-expressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182 overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase1 (PARP1). Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor. Finally, a clinical-grade PARP1 inhibitor impacts outgrowth of miR-182 expressing tumors in animal models. Together these results suggest that miR-182-mediated down-regulation of BRCA1 impedes DNA repair, and may impact breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citationElkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Regulation of mRNA Translation and Stability by microRNAs
Fabian, M. R., Sonenberg, N., & Filipowicz, W. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060308-103103 · Cited by 3,214
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Cited by
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Self-citationIncomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts
Kingdom, R., & Wright, C. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.920390 · Cited by 287
PARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 269
Drug resistance in ovarian cancer: from mechanism to clinical trial
Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01967-3 · Cited by 255
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Genomic integrity and the ageing brain
Chow, H.-M., & Herrup, K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4020 · Cited by 174
Eukaryotic DNA damage checkpoint activation in response to double-strand breaks
Finn, K., Lowndes, N. F., & Grenon, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0875-3 · Cited by 127
Ning, F.-L., Wang, F., Li, M.-L., Yu, Z.-S., Hao, Y.-Z., & Chen, S.-S. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-143 · Cited by 74
Wang, T.-H., Yeh, C.-T., Ho, J.-Y., Ng, K.-F., & Chen, T.-C. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22286 · Cited by 58
Extracellular Vesicles in Modifying the Effects of Ionizing Radiation
Szatmári, T., Hargitai, R., Sáfrány, G., & Lumniczky, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225527 · Cited by 52
Noncoding RNAs in DNA Repair and Genome Integrity
Wan, G., Liu, Y., Han, C., Zhang, X., & Lu, X. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5514 · Cited by 50
MiR-182-5p protects inner ear hair cells from cisplatin-induced apoptosis by inhibiting FOXO3a
Li, Y., Li, A., Wu, J., He, Y., Yu, H., Chai, R., & Li, H. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.246 · Cited by 46
The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target
Sameti, P., Tohidast, M., Amini, M., Bahojb Mahdavi, S. Z., Najafi, S., & Mokhtarzadeh, A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02972-0 · Cited by 32
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R., Gottipati, P., Muschel, R. J., Beech, J., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., Gorospe, M., Harris, A. L., Helleday, T., & Chowdhury, D.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 41
- Issue
- 2
- Pages
- 210-220
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2118723994
- Cited by
- 430
- References
- 70
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.